Sign in
CompletedNo phase

Detection and Prevalence of Human Papillomavirus (HPV) in Seminal Plasma and/or on Sperm in Men Undergoing Treatment With IVF/ICSI.

Key facts

Who runs it
Vastra Gotaland Region
Where
Sweden1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
260 people enrolled
Started
1 Jan 2023
Ended
28 Mar 2024
Type of study
Observational, 2 groups
Treatments tested
  • HPV exposure
Record updated
26 April 2024

Who can take part

Age
18 years to 60 years
Sex
Men only

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Over the course of one year, the study will include men undergoing infertility treatment with IVF/ICSI and fresh ejaculated sperm at Sahlgrenska University Hospital (SU), Gothenburg, Sweden

Who cannot take part

  • Men undergoing sperm freezing for fertility preservation purposes or possessing previously frozen sperm
  • Men for whom treatment with preimplantation genetic testing (PGT) or egg donation is planned
  • Men undergoing IVF/ICSI treatments with surgically extracted sperm
  • Sperm donors

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This observational study aims to investigate the presence of HPV DNA in semen samples from men undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment. It focuses on understanding the impact of HPV on male fertility and embryo development following IVF/ICSI. The primary goal is to determine the prevalence of HPV-positive (HPV+) semen samples among men seeking infertility treatment with IVF/ICSI. Additionally, the study aims to compare semen characteristics between HPV-positive and HPV-negative (HPV-) samples and assess the embryological outcomes after IVF/ICSI in these two groups.

Read full original descriptionShow less

Participants in this study will include men receiving IVF/ICSI treatment and providing fresh ejaculated sperm at Sahlgrenska University Hospital in Gothenburg, Sweden, over one year. Those undergoing treatments with surgically extracted sperm, sperm freezing for fertility preservation, or planning treatments involving preimplantation genetic testing or egg donation will be excluded.

The study will involve analyzing HPV DNA in semen samples through PCR, utilizing the most effective method for HPV DNA detection previously identified in a pilot study. Sperm samples collected during infertility investigations and IVF/ICSI treatments will undergo gradient centrifugation to separate different components. A portion of the sperm sample will be preserved for PCR analysis to detect HPV DNA, while the rest will be used for IVF/ICSI procedures. The results from the PCR analyses will be correlated with semen characteristics and the outcomes of IVF/ICSI treatment. Furthermore, the samples will be stored for potential future analyses related to HPV-related biomarkers for up to 5 years at Biobank.

The 2 groups in the trial

  • Men with HPV-positive (HPV+) semen samples

    Treatment: HPV exposure

  • Men with HPV-negative (HPV-) semen samples

    Treatment: HPV exposure

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Detection and Prevalence of Human Papillomavirus (HPV) in Seminal Plasma and/or on Sperm in Men Undergoing Treatment With IVF/ICSI in Southwestern Sweden: a Prospective Study.
Publications
Record updated
26 April 2024